Inflazome Ltd.

The island nation has caught the interest of international investors and pharmas. Will this be the moment its biotech accelerates?

Takeaways from Bio€quity Europe on the latest BioCentury This Week

‘Pragmatic’ deal gives Novo set of cardiometabolic, kidney and liver diseases, while Versant-backed Ventus keeps indications within biotech’s scope

Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more

Plus: HiberCell, Isarna, Genenta and ImmunOs

Forbion joins the ranks of European life sciences VCs raising record funds this year

NVF’s 2020 liquidity events could be a sign that its strategic shift and new team are moving in the right direction

Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year

Start-up obtains S1PR modulator from Kyorin

On the back of seven liquidity events in the past four months, Longitude Capital has closed its largest fund to date at $585 million. Managing Director Patrick Enright told BioCentury Longitude